In light of the toxicity risk predicted above, and hoping to define a potential therapeutic window of FOLR1(Hi) TCB, we performed the same study with chips seeded with the high FOLR1 expressing ovarian carcinoma cell line, HeLa, previously used to assess drug efficacy (Geiger et al., 2020). The gene discussed is FOLR1; the disease is ovarian carcinoma.